Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 4,773 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HIV Clear all
Completed No phase listed Observational Accepts healthy volunteers

Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers

NCT00027482
View directory record Official record
Conditions
Healthy, HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC

NCT00000679
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Harbor City, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 22, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional

Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial

NCT07125235
View directory record Official record
Conditions
Behavioral Intervention, Viral Suppression of HIV Infection, ART Adherence
Interventions
reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention, urine tenofovir point-of-care self-test
Behavioral · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 1:21 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

#TranscendentHealth: A Text Messaging Pregnancy Prevention Program for Transgender Boys

NCT07681908
View directory record Official record
Conditions
Pregnancy (Unwanted), Sexually Transmitted Disease (STD), HIV Infection, Sexual Behavior
Interventions
#TranscendentHealth, Universal Sexual Health Program
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Clemente, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 1:21 AM EDT
Recruiting Phase 4 Interventional

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

NCT07199335
View directory record Official record
Conditions
HIV, Substance Use Disorder (SUD), Injection Drug Use
Interventions
APRETUDE (cabotegravir)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

NCT05576350
View directory record Official record
Conditions
Risk Behavior, Alcohol Use Disorder, HIV Infections
Interventions
Smartphone Based Alcohol Monitoring (SAM), Tracking and Reducing Alcohol Consumption (TRAC), TRAC-ER
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 35 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Not applicable Interventional

A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia

NCT00001991
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

NCT00001013
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
23
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Not applicable Interventional

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)

NCT00002060
View directory record Official record
Conditions
HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

NCT03329560
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral fecal microbiota transplantation
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 1Phase 2 Interventional

Reducing HIV Risk Among Pregnant Women in Drug Treatment

NCT00332813
View directory record Official record
Conditions
HIV Risk Behavior
Interventions
HIV Risk Behavior Intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 22, 2026, 1:21 AM EDT
Terminated Phase 2 Interventional

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

NCT00002420
View directory record Official record
Conditions
HIV Infections
Interventions
Emivirine, Hydroxyurea, Delavirdine mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Oct 22, 2026, 1:21 AM EDT
Completed No phase listed Observational

Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection

NCT01350648
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

NCT00000916
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Hydroxyurea, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
34
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients

NCT00000748
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
24
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

NCT00002399
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Posaconazole, Fluconazole
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Substance Abuse Treatment to HIV Care (SAT2HIV): The Implementation & Sustainment Facilitation Experiment

NCT03120598
View directory record Official record
Conditions
Substance Use
Interventions
ATTC strategy, ISF strategy
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
39
States / cities
Phoenix, Arizona • Claremont, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 22, 2026, 1:21 AM EDT
Terminated Phase 4 Interventional

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

NCT00781287
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3-drug anti-HIV therapy, Raltegravir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

GW873140 to Treat HIV-1 Infected Adults

NCT00076284
View directory record Official record
Conditions
HIV Infections
Interventions
GW873140
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

HIV and HCV Intervention In Drug Treatment Settings - 1

NCT00102349
View directory record Official record
Conditions
Behavior Therapy
Interventions
Behavior Therapy
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
8
States / cities
Denver, Colorado • Greeley, Colorado • Fall River, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Efficacy of Group Intervention to Reduce Stress Symptoms

NCT00611338
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, HIV Infections
Interventions
HIV Skills-based Prevention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

NCT02345226
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Not applicable Interventional

A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)

NCT00001008
View directory record Official record
Conditions
HIV Infections
Interventions
Methadone hydrochloride, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 22, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

NCT01950325
View directory record Official record
Conditions
HIV-1 Infection, Neutralizing Antibody, Monoclonal Antibody, Viral Load, HIV Antibodies
Interventions
VRC-HIVMAB060-00-AB
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 1:21 AM EDT